Importance Of Adherence To Bcr-abl Tyrosine-kinase Inhibitors In The Treatment Of Chronic Myeloid Leukemia

Treatment of chronic myeloid leukemia with BCR-ABL tyrosine kinase inhibitors requires full adherence in order to maximize the likelihood of achieving optimal responses, and to minimize healthcare costs. In this article, we review some of the methods available for assessing compliance, the main consequences of nonadherence on treatment outcomes, major factors commonly associated with poor compliance, a few successful measures for improving adherence and the most accepted recommendations for proactively managing adverse events. © 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. All rights reserved.3615459Cornelison, M., Jabbour, E.J., Welch, M.A., Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: The role of the midlevel practitioner (2012) J Support Oncol, 10 (1), pp. 14-24Hughes, T.P., Branford, S., Monitoring disease response to tyrosine kinase inhibitor therapy in CML (2009) Hematology Am Soc Hematol Educ Program, pp. 477-487Quintas-Cardama, A., Cortes, J.E., Kantarjian, H., Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia (2008) Clin Lymphoma Myeloma, (SUPPL. 3), pp. S82-S88Bordonaro, S., Raiti, F., Di, M.A., Lopiano, C., Romano, F., Pumo, V., Active home-based cancer treatment (2012) J Multidiscip Healthc, 5, pp. 137-143Marin, D., Bazeos, A., Mahon, F.X., Eliasson, L., Milojkovic, D., Bua, M., Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib (2010) J Clin Oncol, 28 (14), pp. 2381-2388(2003) Adherence to Long-term Therapies: Evidence For Action [Internet], , http://apps.who.int/iris/bitstream/10665/42682/1/9241545992.pdf, World Health Organization, [cited 2012 Nov 29]. Available fromNoens, L., van Lierde, M.A., de Bock, R., Verhoef, G., Zachee, P., Berneman, Z., Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study (2009) Blood, 113 (22), pp. 5401-5411Partridge, A.H., Avorn, J., Wang, P.S., Winer, E.P., Adherence to therapy with oral antineoplastic agents (2002) J Natl Cancer Inst, 94 (9), pp. 652-661. , Comment in: J Natl Cancer Inst. 200294(21):1652author reply 1652Ruddy, K., Mayer, E., Partridge, A., Patient adherence and persistence with oral anticancer treatment (2009) CA Cancer J Clin, 59 (1), pp. 56-66Wang, P.S., Benner, J.S., Glynn, R.J., Winkelmayer, W.C., Mogun, H., Avorn, J., How well do patients report noncompliance with antihypertensive medications?: A comparison of self-report versus filled prescriptions (2004) Pharmacoepidemiol Drug Saf, 13 (1), pp. 11-19Osterberg, L., Blaschke, T., Adherence to medication (2005) N Engl J Med, 353 (5), pp. 487-497. , Comment in: N Engl J Med. 2005;353(18):1972-4author reply 1972-4Pullar, T., Kumar, S., Tindall, H., Feely, M., Time to stop counting the tablets? (1989) Clin Pharmacol Ther, 46 (2), pp. 163-168. , Comment in: Clin Pharmacol Ther. 199047(4):547Rudd, P., Byyny, R.L., Zachary, V., Loverde, M.E., Titus, C., Mitchell, W.D., The natural history of medication compliance in a drug trial: Limitations of pill counts (1989) Clin Pharmacol Ther, 46 (2), pp. 169-176Ibrahim, A.R., Eliasson, L., Apperley, J.F., Milojkovic, D., Bua, M., Szydlo, R., Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy (2011) Blood, 117 (14), pp. 3733-3736Ganesan, P., Sagar, T.G., Dubashi, B., Rajendranath, R., Kannan, K., Cyriac, S., Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia (2011) Am J Hematol, 86 (6), pp. 471-474Yood, M.U., Oliveria, S.A., Cziraky, M., Hirji, I., Hamdan, M., Davis, C., Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia (2012) Curr Med Res Opin, 28 (2), pp. 213-219. , Comment in: Curr Med Res Opin. 2012;28(7):1164author reply 1164-5Darkow, T., Henk, H.J., Thomas, S.K., Feng, W., Baladi, J.F., Goldberg, G.A., Treatment interruptions and nonadherence with imatinib and associated healthcare costs: A retrospective analysis among managed care patients with chronic myelogenous leukaemia (2007) Pharmacoeconomics, 25 (6), pp. 481-496Wu, E.Q., Johnson, S., Beaulieu, N., Arana, M., Bollu, V., Guo, A., Healthcare resource utilization and costs associated with nonadherence to imatinib treatment in chronic myeloid leukemia patients (2010) Curr Med Res Opin, 26 (1), pp. 61-69Eliasson, L., Clifford, S., Barber, N., Marin, D., Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed (2011) Leuk Res, 35 (5), pp. 626-630Kelley, R.K., Venook, A.P., Nonadherence to imatinib during an economic downturn (2010) N Engl J Med, 363 (6), pp. 596-598Efficace, F., Baccarani, M., Rosti, G., Cottone, F., Castagnetti, F., Breccia, M., Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: An observational patient-centered outcome study (2012) Br J Cancer, 107 (6), pp. 904-909. , Comment in: Br J Cancer. 2012;107(6):901-3Jabbour, E., Deininger, M., Hochhaus, A., Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (2011) Leukemia, 25 (2), pp. 201-210Jonsson, S., Olsson, B., Soderberg, J., Wadenvik, H., Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study (2012) Ann Hematol, 91 (5), pp. 679-685Moon, J.H., Sohn, S.K., Kim, S.N., Park, S.Y., Yoon, S.S., Kim, I.H., Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients (2012) Med Oncol, 29 (2), pp. 1179-1185(2013) NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®)-Chronic Myelogenous Leukemia, , http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf, The National Comprehensive Cancer Network, Version 2, [Internet]. 2013 [cited 2012 Nov 29] Available fromRosti, G., Castagnetti, F., Gugliotta, G., Palandri, F., Baccarani, M., Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML (2012) Cancer Treat Rev, 38 (3), pp. 241-248Galinsky, I., Buchanan, S., Practical management of dasatinib for maximum patient benefit (2009) Clin J Oncol Nurs, 13 (3), pp. 329-33